Overview

Effectiveness Study of Nivolumab Compared to Chemotherapy in Patients With Relapsed Small-cell Lung Cancer

Status:
Active, not recruiting
Trial end date:
2022-01-28
Target enrollment:
Participant gender:
Summary
The purpose of this study is to compare the overall survival of nivolumab versus chemotherapy in subjects with relapsed SCLC.
Phase:
Phase 3
Details
Lead Sponsor:
Bristol-Myers Squibb
Collaborator:
Ono Pharmaceutical Co. Ltd
Treatments:
Amrubicin
Antibodies, Monoclonal
Nivolumab
Topotecan